Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Equity Average (2016 - 2025)

Historic Equity Average for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to $173.5 million.

  • Altimmune's Equity Average rose 2135.65% to $173.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.5 million, marking a year-over-year increase of 2135.65%. This contributed to the annual value of $158.8 million for FY2024, which is 1628.53% down from last year.
  • Latest data reveals that Altimmune reported Equity Average of $173.5 million as of Q3 2025, which was up 2135.65% from $151.8 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Equity Average registered a high of $243.9 million during Q2 2021, and its lowest value of $128.4 million during Q4 2024.
  • For the 5-year period, Altimmune's Equity Average averaged around $180.9 million, with its median value being $176.5 million (2023).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 44030.03% in 2021, then plummeted by 2761.75% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Equity Average stood at $204.2 million in 2021, then fell by 4.43% to $195.2 million in 2022, then decreased by 11.74% to $172.2 million in 2023, then decreased by 25.43% to $128.4 million in 2024, then soared by 35.07% to $173.5 million in 2025.
  • Its Equity Average stands at $173.5 million for Q3 2025, versus $151.8 million for Q2 2025 and $132.8 million for Q1 2025.